ImVisioN Therapeutics AG is a Swiss, clinical stage immunotherapy company developing novel treatments to cure allergies.

The Company is the pioneer in intralymphatic immunotherapy (ILIT ™), a proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. ILIT ™ is clinically proven and has been shown to be a safer, more efficacious and more convenient means of delivering allergy therapeutics. By applying another proprietary technology, Modular Antigen Transportation ™ (MAT ™), ImVisioN leverages the potential of ILIT ™ to develop drugs that use allergens safely for specific and highly effective antigen presentation. ImVisioN’s lead product is for the treatment of cat dander allergy and the Company has programs addressing birch pollen and house dust mite allergies. The Company’s proprietary technology platforms are applicable to further allergy targets, which may be addressed in the future.

latest news

• 19.03.2009
  Positive Phase I Clinical Results for Treatment of Cat Dander Allergy...
• 10.11.2008
  ILIT Proof of Concept published in PNAS...
• 12.09.2008
  Financing and clinical study enroled...
• 06.02.2007
  EU patent for MAT™ technology granted ...